STOCK TITAN

[S-8] AtriCure, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

On 30 Jul 2025 AtriCure, Inc. ("ATRC") filed a Form S-8 with the SEC to register 1,700,000 additional shares of common stock for issuance under its 2023 Stock Incentive Plan. Because the company is a large accelerated filer, the shares become eligible for grant immediately upon effectiveness.

The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and a recent Form 8-K, and includes standard undertakings and indemnification language. Keating Muething & Klekamp PLL supplied the legal opinion, while Deloitte & Touche LLP provided the auditor’s consent. No new financial statements, pricing terms or selling shareholder information are presented.

The registration expands the equity pool used to attract, retain and motivate employees and directors; however, issuance of the newly registered shares could dilute existing shareholders when awards vest or are exercised.

Il 30 luglio 2025, AtriCure, Inc. ("ATRC") ha depositato presso la SEC un modulo Form S-8 per registrare 1.700.000 azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari 2023. Essendo la società un large accelerated filer, le azioni diventano immediatamente eleggibili per la concessione al momento dell'efficacia.

La documentazione fa riferimento al modulo 10-K 2024 della società, ai moduli 10-Q 2025 e a un recente modulo 8-K, includendo inoltre le consuete dichiarazioni di impegno e clausole di indennizzo. L'opinione legale è stata fornita da Keating Muething & Klekamp PLL, mentre Deloitte & Touche LLP ha concesso il consenso dell'auditor. Non sono stati presentati nuovi bilanci, termini di prezzo o informazioni su azionisti venditori.

La registrazione amplia il pool azionario utilizzato per attrarre, trattenere e motivare dipendenti e amministratori; tuttavia, l'emissione delle nuove azioni registrate potrebbe diluire gli azionisti esistenti quando le assegnazioni maturano o vengono esercitate.

El 30 de julio de 2025, AtriCure, Inc. ("ATRC") presentó ante la SEC un Formulario S-8 para registrar 1.700.000 acciones adicionales comunes para emisión bajo su Plan de Incentivos de Acciones 2023. Debido a que la compañía es un large accelerated filer, las acciones se vuelven elegibles para otorgamiento inmediatamente al entrar en vigencia.

La presentación incorpora por referencia el Formulario 10-K 2024 de la empresa, los Formularios 10-Q 2025 y un reciente Formulario 8-K, e incluye compromisos estándar y cláusulas de indemnización. Keating Muething & Klekamp PLL proporcionó la opinión legal, mientras que Deloitte & Touche LLP otorgó el consentimiento del auditor. No se presentan nuevos estados financieros, términos de precio ni información sobre accionistas vendedores.

El registro amplía el grupo de acciones utilizado para atraer, retener y motivar a empleados y directores; sin embargo, la emisión de las acciones recién registradas podría diluir a los accionistas existentes cuando las concesiones se consoliden o ejerzan.

2025년 7월 30일, AtriCure, Inc.("ATRC")는 2023년 주식 인센티브 플랜에 따라 1,700,000주의 보통주 추가 발행을 위해 SEC에 Form S-8을 제출했습니다. 회사가 대형 가속 제출자(large accelerated filer)이기 때문에, 해당 주식은 효력 발생 즉시 부여 대상이 됩니다.

이번 제출은 회사의 2024년 Form 10-K, 2025년 Form 10-Q, 최근 Form 8-K를 참조하며, 표준 약속과 면책 조항을 포함합니다. 법률 의견은 Keating Muething & Klekamp PLL이 제공했고, Deloitte & Touche LLP가 감사인의 동의를 제공했습니다. 새로운 재무제표, 가격 조건 또는 판매 주주 정보는 포함되지 않았습니다.

이번 등록은 직원과 이사들을 유치, 유지 및 동기 부여하는 데 사용되는 주식 풀을 확장하지만, 새로 등록된 주식의 발행은 보상 수령 시 기존 주주들의 지분 희석을 초래할 수 있습니다.

Le 30 juillet 2025, AtriCure, Inc. (« ATRC ») a déposé auprès de la SEC un formulaire S-8 pour enregistrer 1 700 000 actions ordinaires supplémentaires à émettre dans le cadre de son plan d'incitation en actions 2023. Étant donné que la société est un large accelerated filer, les actions deviennent immédiatement éligibles à l'attribution dès l'entrée en vigueur.

Le dépôt intègre par référence le formulaire 10-K 2024 de la société, les formulaires 10-Q 2025 ainsi qu'un récent formulaire 8-K, et inclut les engagements standards et les clauses d'indemnisation. L'avis juridique a été fourni par Keating Muething & Klekamp PLL, tandis que Deloitte & Touche LLP a donné le consentement de l'auditeur. Aucun nouvel état financier, condition de prix ou information sur les actionnaires vendeurs n'est présenté.

Cette inscription élargit le pool d'actions utilisé pour attirer, retenir et motiver les employés et administrateurs ; toutefois, l'émission des actions nouvellement enregistrées pourrait diluer les actionnaires existants lorsque les attributions seront acquises ou exercées.

Am 30. Juli 2025 reichte AtriCure, Inc. ("ATRC") bei der SEC ein Formular S-8 ein, um 1.700.000 zusätzliche Stammaktien zur Ausgabe im Rahmen seines Aktienanreizplans 2023 zu registrieren. Da das Unternehmen ein large accelerated filer ist, werden die Aktien mit Wirksamkeit sofort zur Gewährung berechtigt.

Die Einreichung verweist auf den 2024er Form 10-K-Bericht des Unternehmens, die 2025er Form 10-Q-Berichte sowie ein aktuelles Form 8-K und enthält Standardzusagen sowie Haftungsfreistellungen. Die Rechtsmeinung wurde von Keating Muething & Klekamp PLL bereitgestellt, die Zustimmung des Wirtschaftsprüfers von Deloitte & Touche LLP. Es werden keine neuen Finanzberichte, Preisbedingungen oder Informationen zu verkaufenden Aktionären vorgelegt.

Die Registrierung erweitert den Aktienpool, der zur Gewinnung, Bindung und Motivation von Mitarbeitern und Direktoren genutzt wird; die Ausgabe der neu registrierten Aktien könnte jedoch zu einer Verwässerung der bestehenden Aktionäre führen, wenn Auszeichnungen fällig werden oder ausgeübt werden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine S-8 adds 1.7 M shares to incentive plan; neutral impact—talent retention vs. dilution.

The filing is administrative, registering additional shares for the 2023 Stock Incentive Plan. Such actions are common for growth firms that rely on equity compensation. While providing flexibility to issue awards that align employee interests, the move can incrementally dilute existing holders as shares are issued. No valuation, cash-flow or operational data changed; therefore, the near-term investment thesis remains intact.

TL;DR: Governance-sound filing; indemnification and insurance provisions standard, no red flags.

The document restates customary Delaware indemnification rights, mirrors the company’s charter and bylaws, and discloses that counsel owns no ATRC stock—mitigating conflict-of-interest concerns. Inclusion of a full power-of-attorney for officers is standard. Overall, the governance posture appears compliant and shareholder-friendly, though investors should monitor future dilution from award issuance.

Il 30 luglio 2025, AtriCure, Inc. ("ATRC") ha depositato presso la SEC un modulo Form S-8 per registrare 1.700.000 azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari 2023. Essendo la società un large accelerated filer, le azioni diventano immediatamente eleggibili per la concessione al momento dell'efficacia.

La documentazione fa riferimento al modulo 10-K 2024 della società, ai moduli 10-Q 2025 e a un recente modulo 8-K, includendo inoltre le consuete dichiarazioni di impegno e clausole di indennizzo. L'opinione legale è stata fornita da Keating Muething & Klekamp PLL, mentre Deloitte & Touche LLP ha concesso il consenso dell'auditor. Non sono stati presentati nuovi bilanci, termini di prezzo o informazioni su azionisti venditori.

La registrazione amplia il pool azionario utilizzato per attrarre, trattenere e motivare dipendenti e amministratori; tuttavia, l'emissione delle nuove azioni registrate potrebbe diluire gli azionisti esistenti quando le assegnazioni maturano o vengono esercitate.

El 30 de julio de 2025, AtriCure, Inc. ("ATRC") presentó ante la SEC un Formulario S-8 para registrar 1.700.000 acciones adicionales comunes para emisión bajo su Plan de Incentivos de Acciones 2023. Debido a que la compañía es un large accelerated filer, las acciones se vuelven elegibles para otorgamiento inmediatamente al entrar en vigencia.

La presentación incorpora por referencia el Formulario 10-K 2024 de la empresa, los Formularios 10-Q 2025 y un reciente Formulario 8-K, e incluye compromisos estándar y cláusulas de indemnización. Keating Muething & Klekamp PLL proporcionó la opinión legal, mientras que Deloitte & Touche LLP otorgó el consentimiento del auditor. No se presentan nuevos estados financieros, términos de precio ni información sobre accionistas vendedores.

El registro amplía el grupo de acciones utilizado para atraer, retener y motivar a empleados y directores; sin embargo, la emisión de las acciones recién registradas podría diluir a los accionistas existentes cuando las concesiones se consoliden o ejerzan.

2025년 7월 30일, AtriCure, Inc.("ATRC")는 2023년 주식 인센티브 플랜에 따라 1,700,000주의 보통주 추가 발행을 위해 SEC에 Form S-8을 제출했습니다. 회사가 대형 가속 제출자(large accelerated filer)이기 때문에, 해당 주식은 효력 발생 즉시 부여 대상이 됩니다.

이번 제출은 회사의 2024년 Form 10-K, 2025년 Form 10-Q, 최근 Form 8-K를 참조하며, 표준 약속과 면책 조항을 포함합니다. 법률 의견은 Keating Muething & Klekamp PLL이 제공했고, Deloitte & Touche LLP가 감사인의 동의를 제공했습니다. 새로운 재무제표, 가격 조건 또는 판매 주주 정보는 포함되지 않았습니다.

이번 등록은 직원과 이사들을 유치, 유지 및 동기 부여하는 데 사용되는 주식 풀을 확장하지만, 새로 등록된 주식의 발행은 보상 수령 시 기존 주주들의 지분 희석을 초래할 수 있습니다.

Le 30 juillet 2025, AtriCure, Inc. (« ATRC ») a déposé auprès de la SEC un formulaire S-8 pour enregistrer 1 700 000 actions ordinaires supplémentaires à émettre dans le cadre de son plan d'incitation en actions 2023. Étant donné que la société est un large accelerated filer, les actions deviennent immédiatement éligibles à l'attribution dès l'entrée en vigueur.

Le dépôt intègre par référence le formulaire 10-K 2024 de la société, les formulaires 10-Q 2025 ainsi qu'un récent formulaire 8-K, et inclut les engagements standards et les clauses d'indemnisation. L'avis juridique a été fourni par Keating Muething & Klekamp PLL, tandis que Deloitte & Touche LLP a donné le consentement de l'auditeur. Aucun nouvel état financier, condition de prix ou information sur les actionnaires vendeurs n'est présenté.

Cette inscription élargit le pool d'actions utilisé pour attirer, retenir et motiver les employés et administrateurs ; toutefois, l'émission des actions nouvellement enregistrées pourrait diluer les actionnaires existants lorsque les attributions seront acquises ou exercées.

Am 30. Juli 2025 reichte AtriCure, Inc. ("ATRC") bei der SEC ein Formular S-8 ein, um 1.700.000 zusätzliche Stammaktien zur Ausgabe im Rahmen seines Aktienanreizplans 2023 zu registrieren. Da das Unternehmen ein large accelerated filer ist, werden die Aktien mit Wirksamkeit sofort zur Gewährung berechtigt.

Die Einreichung verweist auf den 2024er Form 10-K-Bericht des Unternehmens, die 2025er Form 10-Q-Berichte sowie ein aktuelles Form 8-K und enthält Standardzusagen sowie Haftungsfreistellungen. Die Rechtsmeinung wurde von Keating Muething & Klekamp PLL bereitgestellt, die Zustimmung des Wirtschaftsprüfers von Deloitte & Touche LLP. Es werden keine neuen Finanzberichte, Preisbedingungen oder Informationen zu verkaufenden Aktionären vorgelegt.

Die Registrierung erweitert den Aktienpool, der zur Gewinnung, Bindung und Motivation von Mitarbeitern und Direktoren genutzt wird; die Ausgabe der neu registrierten Aktien könnte jedoch zu einer Verwässerung der bestehenden Aktionäre führen, wenn Auszeichnungen fällig werden oder ausgeübt werden.

As filed with the Securities and Exchange Commission on July 30, 2025

Registration No. 333-    

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ATRICURE, INC.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   34-1940305

(State Or Other Jurisdiction Of

Incorporation Or Organization)

 

(IRS Employer

Identification Number)

7555 Innovation Way

Mason, Ohio 45040

(513) 755-4100

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

ATRICURE, INC.

2023 STOCK INCENTIVE PLAN

(Full title of the Plan)

 

 

Angela L. Wirick

Chief Financial Officer

AtriCure, Inc.

7555 Innovation Way

Mason, Ohio 45040

(513) 755-4100

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

F. Mark Reuter

Keating Muething & Klekamp PLL

One East Fourth Street, Suite 1400

Cincinnati, Ohio 45202

(513) 579-6469

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Check one:

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

This registration statement on Form S-8 (“Registration Statement”) is filed by AtriCure, Inc., a Delaware corporation (the “Registrant” or the “Company”), for the purpose of registering an additional 1,700,000 shares of Common Stock, par value $.001 per share (the “Shares”), to be issued to eligible participants pursuant to the Registrant’s 2023 Stock Incentive Plan (as amended from time to time, the “2023 Plan”).

The document(s) containing the information required by Item 1 of Form S-8 and the statement of availability of registrant information and any other information required by Item 2 of Form S-8 shall be sent or given to participants as specified by Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with Rule 428 and the requirements of Part I of Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. The Registrant will maintain a file of such documents in accordance with the provisions of Rule 428. Upon request, the Registrant shall furnish the Commission or its staff a copy or copies of all of the documents included in such file.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3.

Incorporation of Documents by Reference

The following documents filed by the Registrant with the Commission are incorporated herein by reference and made a part hereof:

 

  1.

Annual Report on Form 10-K for the fiscal year ended December 31, 2024;

 

  2.

Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025;

 

  3.

Current Report(s) on Form 8-K filed on May 20, 2025;

 

  4.

The description of the Common Stock contained in the Registration Statement on Form 8-A filed on August 1, 2005 registering the Registrant’s Common Stock under Section  12 of the Securities Exchange Act of 1934, as supplemented by Exhibit 4.1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents, except as to any portion of any future statement, report or document that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be a part of this registration statement from the date of filing of such document with the SEC until the information contained therein is superseded or updated by any subsequently filed document that is incorporated by reference herein. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement. Under no circumstances will any information filed under Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.


Item 4.

Description of Securities

Not Applicable.

 

Item 5.

Interests of Named Experts and Counsel

The legality of the Common Stock offered hereby will be passed upon for the Registrant by Keating Muething & Klekamp PLL, One East Fourth Street, Suite 1400, Cincinnati, Ohio 45202. Attorneys of Keating Muething & Klekamp PLL participating in matters relating to this Form S-8 own no shares of the Registrant’s Common Stock.

 

Item 6.

Indemnification of Directors and Officers

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Article VII of the Registrant’s Restated Certificate of Incorporation provides for indemnification by the Registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law. In addition, the Registrant has entered into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s Restated Certificate of Incorporation and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought.

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its Certificate of Incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director derived an improper personal benefit. The Registrant’s Restated Certificate of Incorporation provides for such limitation of liability.

The Registrant maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act, and (b) to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to the above indemnification provisions or otherwise as a matter of law.

Article IX of the Registrant’s Amended and Restated Bylaws provides as follows:

ARTICLE IX - INDEMNIFICATION

9.1 INDEMNIFICATION OF DIRECTORS AND OFFICERS.

The corporation shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the corporation to provide broader indemnification rights than such law permitted the


corporation to provide prior to such amendment), any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, or any other threatened, pending or completed proceeding, whether of a civil, criminal, administrative, legislative, investigative or other nature (a “Proceeding”) by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the corporation or, while serving as a director or officer of the corporation, is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, or other enterprise or non-profit entity, including service with respect to employee benefit plans (an “indemnitee”), whether the basis of such Proceeding is alleged action in an official capacity as a director or officer of the corporation or in any other capacity while serving as a director or officer of the corporation, against all liability and loss suffered and expenses (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred by such indemnitee in connection with any such Proceeding. Notwithstanding the previous sentence, the corporation shall not be required to indemnify an indemnitee in connection with a Proceeding (or part thereof) initiated by such indemnitee unless (i) the Proceeding (or part thereof) was authorized by the Board, except as provided in Section 9.4 of this Article IX with respect to proceedings to enforce rights to advancement or indemnification or (ii) the Proceeding (or part thereof) is initiated to enforce rights to indemnification or advancement of expenses as provided under Section 9.4 below or is a compulsory counterclaim brought by such indemnitee. Any reference to an officer of the corporation in this Article IX shall be deemed to refer exclusively to the chief executive officer, president, chief financial officer, secretary, treasurer, and any other officer of the corporation elected or appointed as such by the Board pursuant to Section 5.2 of these bylaws.

9.2 INDEMNIFICATION OF OTHERS.

The corporation shall have the power to indemnify and hold harmless and advance expenses to, to the extent and in the manner permitted by applicable law as it presently exists or may hereafter be amended, any employee or agent of the corporation who was or is made or is threatened to be made a party or is otherwise involved in any Proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred by such person in connection with any such Proceeding.

9.3 PREPAYMENT OF EXPENSES.

The corporation shall pay the expenses incurred by or on behalf of an indemnitee, and may pay the expenses incurred by any current or former employee or agent of the corporation, in defending any Proceeding in advance of its final disposition; provided, however, that the payment of expenses incurred by or on behalf of an indemnitee in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the indemnitee to repay all amounts advanced if it should be ultimately determined by final judicial decision from which there is no further right of appeal that an indemnitee is not entitled to be indemnified under this Article IX or otherwise.

9.4 DETERMINATION; CLAIM.

If a claim for indemnification under this Article IX is not paid to an indemnitee in full within sixty (60) days, or if a claim for any advancement of expenses under this Article IX is not paid in full within twenty (20) days, after a written claim therefor has been received by the corporation, the indemnitee may at any time thereafter file suit against the corporation in the Delaware Court of Chancery seeking an adjudication of entitlement to such indemnification or advancement of expenses. To the fullest extent permitted by law, if successful in whole or in part in any such suit, or in a suit brought by the corporation to recover an advancement


of expenses pursuant to the terms of an undertaking, the indemnitee shall also be entitled to be paid the expense of prosecuting or defending such suit. In any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that the indemnitee has not met any applicable standard of conduct for indemnification set forth in Section 145 of the DGCL. In any suit brought by the corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the corporation shall be entitled to recover such expenses upon a final adjudication that the indemnitee has not met any applicable standard of conduct for indemnification set forth in Section 145 of the DGCL. Neither the failure of the corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in Section 145 of the DGCL, nor an actual determination by the corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under applicable law, this Article IX or otherwise shall be on the corporation.

9.5 NON-EXCLUSIVITY OF RIGHTS.

The rights conferred on any person by this Article IX shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the certificate of incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

9.6 INSURANCE.

The corporation may purchase and maintain insurance, at its expense, to protect itself and any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss asserted against him or her and incurred by him or her in any such capacity, whether or not the corporation would have the power to indemnify him or her against such liability under the provisions of the DGCL.

9.7 AMENDMENT OR REPEAL.

The rights to indemnification and advancement of expenses provided by this Article IX shall not be deemed exclusive of any other rights which any person may have or hereafter acquire under any law, provision of the certificate of incorporation or these bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The rights conferred upon indemnitees in this Article IX shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director or officer of the corporation and shall inure to the benefit of the indemnitee’s heirs, executors and administrators. Any amendment, repeal or modification of the foregoing provisions of this Article IX that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit or eliminate any such right with respect to any Proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, modification or repeal.


9.8 SUBROGATION.

In the event of payment under this Article IX, the corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the indemnitee (excluding insurance obtained on the indemnitee’s own behalf), and the indemnitee shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the corporation effectively to bring suit to enforce such rights.

 

Item 7.

Exemption from Registration Claimed

Not Applicable.

 

Item 8.

Exhibits*

 

  Exhibit 4.1    Restated Certificate of Incorporation (incorporated by reference to the Current Report on Form 8-K, filed on May 14, 2024).
  Exhibit 4.2    Amended and Restated Bylaws (incorporated by reference to Quarterly Report on Form 10-Q filed on July 31, 2024).
  Exhibit 4.3    Description of the Registrant’s Securities Registered Pursuant to Section  12 of the Securities Exchange Act of 1934 (incorporated by reference to Annual Report on Form 10-K filed on February 24, 2020).
  Exhibit 5.1    Opinion of Keating Muething & Klekamp PLL.
 Exhibit 23.1    Consent of Deloitte & Touche LLP.
 Exhibit 23.2    Consent of Keating Muething & Klekamp PLL (included in Exhibit 5).
 Exhibit 24.1    Power of Attorney (included in the signature page).
 Exhibit 99.1    2023 Stock Incentive Plan (incorporated by reference to the Current Report on Form 8-K filed on May 20, 2025).
Exhibit 107.1    Filing Fee Table.

 

*

All Exhibits filed herewith unless otherwise indicated.

 

Item 9.

Undertakings

(a) The undersigned Registrant hereby undertakes

(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities


offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in Mason, Ohio, as of the 30th day of July, 2025.

 

ATRICURE, INC.
By:   /s/ Angela L. Wirick
  Angela L. Wirick
  Chief Financial Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Michael H. Carrel and Angela L. Wirick, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature

  

Title

 

Date

/s/ Michael H. Carrel    President, Chief Executive Officer and   July 30, 2025
Michael H. Carrel    Director (Principal Executive Officer)  
/s/ Angela L. Wirick    Chief Financial Officer   July 30, 2025
Angela L. Wirick    (Principal Financial  
   and Accounting Officer)  
/s/ Robert S. White    Chair of the Board of Directors   July 30, 2025
Robert S. White     
/s/ Regina E. Groves    Director   July 30, 2025
Regina E. Groves     
/s/ B. Kristine Johnson    Director   July 30, 2025
B. Kristine Johnson     


/s/ Shlomo Nachman    Director   July 30, 2025
Shlomo Nachman     
/s/ Karen N. Prange    Director   July 30, 2025
Karen N. Prange     
/s/ Deborah H. Telman    Director   July 30, 2025
Deborah H. Telman     
/s/ Sven A. Wehrwein    Director   July 30, 2025
Sven A. Wehrwein     
/s/ Maggie Yuen    Director   July 30, 2025
Maggie Yuen     

FAQ

How many shares is AtriCure (ATRC) registering in this Form S-8?

The company is registering 1,700,000 additional common shares.

Which plan will use the newly registered shares?

The shares are reserved for the 2023 Stock Incentive Plan.

Does the filing disclose any new financial results for ATRC?

No. The Form S-8 contains no new financial statements or earnings data.

Who provided the legal opinion for the filing and when was it submitted?

Keating Muething & Klekamp PLL issued the opinion; the filing was submitted on 30 Jul 2025.

What is the potential impact on existing shareholders?

Future issuance of the registered shares could increase share count and dilute ownership percentages.
Atricure

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Latest SEC Filings

ATRC Stock Data

1.74B
47.75M
3.49%
98.23%
2.91%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MASON